- Home
- ASC vs ANNX Comparison
ASC vs ANNX Comparison
Compare ASC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- ANNX
- Stock Information
- Founded
- ASC 2010
- ANNX 2011
- Country
- ASC Bermuda
- ANNX United States
- Employees
- ASC N/A
- ANNX N/A
- Industry
- ASC Marine Transportation
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- ANNX Health Care
- Exchange
- ASC Nasdaq
- ANNX Nasdaq
- Market Cap
- ASC 382.7M
- ANNX 362.4M
- IPO Year
- ASC 2013
- ANNX 2020
- Fundamental
- Price
- ASC $9.63
- ANNX $2.04
- Analyst Decision
- ASC Buy
- ANNX Strong Buy
- Analyst Count
- ASC 3
- ANNX 4
- Target Price
- ASC $13.67
- ANNX $12.50
- AVG Volume (30 Days)
- ASC 597.1K
- ANNX 1.4M
- Earning Date
- ASC 05-07-2025
- ANNX 05-12-2025
- Dividend Yield
- ASC 7.18%
- ANNX N/A
- EPS Growth
- ASC N/A
- ANNX N/A
- EPS
- ASC 2.30
- ANNX N/A
- Revenue
- ASC $373,479,000.00
- ANNX N/A
- Revenue This Year
- ASC N/A
- ANNX N/A
- Revenue Next Year
- ASC N/A
- ANNX N/A
- P/E Ratio
- ASC $4.19
- ANNX N/A
- Revenue Growth
- ASC N/A
- ANNX N/A
- 52 Week Low
- ASC $8.32
- ANNX $1.29
- 52 Week High
- ASC $23.19
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- ASC 46.66
- ANNX 53.89
- Support Level
- ASC $9.42
- ANNX $1.92
- Resistance Level
- ASC $9.96
- ANNX $2.21
- Average True Range (ATR)
- ASC 0.30
- ANNX 0.17
- MACD
- ASC -0.06
- ANNX 0.03
- Stochastic Oscillator
- ASC 16.00
- ANNX 63.79
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.